Vince Martin

Vince Martin

InvestorPlace Contributor

Vince Martin has written investing advice for several years, covering stocks across a range of industries. A former registered representative, Martin saw the dot-com bubble inflate and burst in real time, creating a healthy respect for downside risk. He splits his time between Chicago and rural Wisconsin with his wife and three dogs.

Recent Articles

4 Software Stocks to Buy Based on SaaS Strength

By Vince Martin, InvestorPlace Contributor

SaaS is more than just a buzzword. It's an industry sea change and its appeal underpins the bull cases for these four software stocks to buy.

2 Reasons to Buy Spartan Energy Stock — and One to Be Patient

By Vince Martin, InvestorPlace Contributor

SPAQ stock has receded after an initial burst, and looks like a buy on the dip. The question is if investors need to buy the stock just yet.

3 Key Questions to Ask Before Buying Novavax

By Vince Martin, InvestorPlace Contributor

Vaccine approval certainly can drive NVAX stock back to new highs after a recent pullback. But risks go beyond vaccine development.

Arcimoto Could Be Intriguing – On a Bigger Pullback

By Vince Martin, InvestorPlace Contributor

Arcimoto has the potential to find a niche in electric vehicles. But after a 600% rally, Arcimoto stock needs a cheaper price to compensate for the real risks.

Why Fulgent Genetics Stock Can Keep Soaring

By Vince Martin, InvestorPlace Contributor

Fulgent Genetics stock has gained 253% so far this year. Strong growth and a reasonable valuation suggest the rally will continue.

The 4 Best Dividend Aristocrats to Buy Now

By Vince Martin, InvestorPlace Contributor

Dividend aristocrats have increased dividends for at least 25 consecutive years. Here are four of the best dividend aristocrats you can buy.

10 Growth Stocks That Could Seriously Double

By Vince Martin, InvestorPlace Contributor

Growth stocks have been the market's biggest winners. Amid valuation concerns, these 10 stocks still have the potential for 100%-plus gains.

Eli Lilly (Still) Looks Like the Best Buy in Large-Cap Pharma

By Vince Martin, InvestorPlace Contributor

LLY stock has been the best large-cap pharma play in recent years. With a strong pipeline and reasonable valuation, that should continue.

There Are Still Too Many Risks In iBio Stock

By Vince Martin, InvestorPlace Contributor

IBIO stock has retreated sharply in recent weeks, and looks more attractive on the dip. But even cheaper, the stock looks like an avoid.

The One Number That Undercuts the Bull Case for Luckin Stock

By Vince Martin, InvestorPlace Contributor

After it came off a trading halt, Luckin stock had an intriguing, if high-risk, bull case. But a sharply lower cash balance hurts that case.

Load More